Director/PDMR Shareholding

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr R Connor will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Hussain will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Redfern will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Thomas will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.

Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Vallance will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.